DEXCOM INC (DXCM) Research | Aerarium Research

Forward Estimates

EPS Estimates

Current Qtr

$0.61

$0.57$0.66

vs $0.48+26.7%

19 analysts

Next Qtr

$0.67

$0.62$0.70

vs $0.61+10.4%

19 analysts

Current Yr

$2.59

$2.46$2.65

vs $2.09+24.1%

23 analysts

Next Yr

$3.07

$2.79$3.27

vs $2.59+18.6%

23 analysts

Revenue Estimates

Current Qtr

$1.29B

$1.28B$1.30B

vs $1.16B+11.5%

22 analysts

Next Qtr

$1.34B

$1.31B$1.36B

vs $1.21B+10.6%

22 analysts

Current Yr

$5.23B

$5.17B$5.26B

vs $4.66B+12.1%

26 analysts

Next Yr

$5.83B

$5.70B$6.00B

vs $5.23B+11.6%

26 analysts

SEC filings →

View all 10-K, 10-Q, and 8-K filings for DXCM on EDGAR.

DXCM filing events and research context
Filed	Item	Context
Apr 30, 2026	mda_quarterly	Dexcom reported first-quarter 2026 revenue of $1.19 billion, a 15% increase driven by higher disposable sensor volume and global customer growth, though partially offset by pricing headwinds from channel mix and rebate eligibility. Net income rose 89% to $199.5 million, and operating cash flow surged 186% to $525.6 million. Gross profit grew 27% to $750.3 million, benefiting from manufacturing efficiencies, higher production volumes, and improved fixed cost absorption. The company's product portfolio now includes the G7, the G7 15 Day, and Stelo, an over-the-counter biosensor for prediabetes and non-insulin-using Type 2 diabetes patients. Strategic priorities include developing intelligent insulin administration, predictive modeling via machine learning, and expanding into obesity, pregnancy, and hospital settings. Dexcom ended the quarter with $2.42 billion in cash and marketable securities, supporting planned significant capital expenditures for manufacturing facility expansion. Financial performance was further aided by a Malaysia tax holiday, which lowered the effective tax rate. Long-term liabilities include senior convertible notes maturing in May 2028.
Feb 12, 2026	business	Dexcom specializes in continuous glucose monitoring (CGM) systems for diabetes and metabolic health management. Its current portfolio is led by the G7 and G7 15 Day iCGM systems, with a planned transition of all G6 customers to the G7 platform by the end of 2026. The company is expanding its addressable market beyond insulin-dependent patients through Stelo, the first over-the-counter glucose biosensor in the U.S. for adults with prediabetes and Type 2 diabetes. Dexcom leverages a connected ecosystem, integrating its sensors with insulin pumps, smart pens, and wearables. However, the company faces intense competition from Abbott’s Libre and Medtronic’s Simplera systems. Critical financial and operational risks include a projected decline in Medicare reimbursement beginning in 2028 due to the CMS competitive bidding program and a March 2025 FDA warning letter citing manufacturing and quality system non-conformities at its San Diego and Mesa facilities. Furthermore, Dexcom’s supply chain is vulnerable due to its reliance on single-source suppliers for essential components, including application-specific integrated circuits and polymeric membranes. The company continues to scale capacity through a new manufacturing facility in Ireland to support global growth.
Feb 12, 2026	mda	DXCM reported 2025 revenue of $4.66 billion, a 16% increase driven by higher disposable sensor volume and the addition of 600,000 to 700,000 net customers, excluding Stelo. This growth was partially offset by pricing headwinds stemming from channel mix and increased rebate eligibility. Gross profit margin declined slightly to 60.1% due to production yield issues, replacement costs, and supply availability inefficiencies. Operating income grew 52% to $911.8 million, supported by a significant reduction in legal expenses following the December 2024 settlement of a patent infringement lawsuit, which offset higher compensation costs in R&D and SG&A. Net income rose 45% to $836.3 million. The company's effective tax rate was impacted by share-based compensation shortfalls, though partially mitigated by a new tax holiday in Malaysia. Liquidity remains strong through cash flows, convertible notes, and a credit facility. Strategic risks include the ability to scale operations, third-party reimbursement rates, and increased foreign exchange exposure as manufacturing expands in Ireland and Malaysia. Revenue remains subject to Q1 seasonality linked to U.S. insurance deductible resets and flexible spending accounts.

Filed

Item

Context

Apr 30, 2026

mda_quarterly

Dexcom reported first-quarter 2026 revenue of $1.19 billion, a 15% increase driven by higher disposable sensor volume and global customer growth, though partially offset by pricing headwinds from channel mix and rebate eligibility. Net income rose 89% to $199.5 million, and operating cash flow surged 186% to $525.6 million. Gross profit grew 27% to $750.3 million, benefiting from manufacturing efficiencies, higher production volumes, and improved fixed cost absorption. The company's product portfolio now includes the G7, the G7 15 Day, and Stelo, an over-the-counter biosensor for prediabetes and non-insulin-using Type 2 diabetes patients. Strategic priorities include developing intelligent insulin administration, predictive modeling via machine learning, and expanding into obesity, pregnancy, and hospital settings. Dexcom ended the quarter with $2.42 billion in cash and marketable securities, supporting planned significant capital expenditures for manufacturing facility expansion. Financial performance was further aided by a Malaysia tax holiday, which lowered the effective tax rate. Long-term liabilities include senior convertible notes maturing in May 2028.

Feb 12, 2026

business

Dexcom specializes in continuous glucose monitoring (CGM) systems for diabetes and metabolic health management. Its current portfolio is led by the G7 and G7 15 Day iCGM systems, with a planned transition of all G6 customers to the G7 platform by the end of 2026. The company is expanding its addressable market beyond insulin-dependent patients through Stelo, the first over-the-counter glucose biosensor in the U.S. for adults with prediabetes and Type 2 diabetes. Dexcom leverages a connected ecosystem, integrating its sensors with insulin pumps, smart pens, and wearables. However, the company faces intense competition from Abbott’s Libre and Medtronic’s Simplera systems. Critical financial and operational risks include a projected decline in Medicare reimbursement beginning in 2028 due to the CMS competitive bidding program and a March 2025 FDA warning letter citing manufacturing and quality system non-conformities at its San Diego and Mesa facilities. Furthermore, Dexcom’s supply chain is vulnerable due to its reliance on single-source suppliers for essential components, including application-specific integrated circuits and polymeric membranes. The company continues to scale capacity through a new manufacturing facility in Ireland to support global growth.

Feb 12, 2026

mda

DXCM reported 2025 revenue of $4.66 billion, a 16% increase driven by higher disposable sensor volume and the addition of 600,000 to 700,000 net customers, excluding Stelo. This growth was partially offset by pricing headwinds stemming from channel mix and increased rebate eligibility. Gross profit margin declined slightly to 60.1% due to production yield issues, replacement costs, and supply availability inefficiencies. Operating income grew 52% to $911.8 million, supported by a significant reduction in legal expenses following the December 2024 settlement of a patent infringement lawsuit, which offset higher compensation costs in R&D and SG&A. Net income rose 45% to $836.3 million. The company's effective tax rate was impacted by share-based compensation shortfalls, though partially mitigated by a new tax holiday in Malaysia. Liquidity remains strong through cash flows, convertible notes, and a credit facility. Strategic risks include the ability to scale operations, third-party reimbursement rates, and increased foreign exchange exposure as manufacturing expands in Ireland and Malaysia. Revenue remains subject to Q1 seasonality linked to U.S. insurance deductible resets and flexible spending accounts.

Forward Estimates

DXCM filing events and research context

Keep researching DXCM

Related tickers

Related explainers

Forward Estimates